<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01904903</url>
  </required_header>
  <id_info>
    <org_study_id>ML 28685</org_study_id>
    <nct_id>NCT01904903</nct_id>
  </id_info>
  <brief_title>Cardiac Safety Study in Patients With HER2 + Breast Cancer</brief_title>
  <acronym>SAFE-HEaRt</acronym>
  <official_title>SAFE-HEaRt: A Pilot Study Assessing the Cardiac SAFEty of HER2 Targeted Therapy in Patients With HER2 Positive Breast Cancer and Reduced Left Ventricular Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medstar Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HER2 positive breast cancer cells have more HER2 receptor (a protein on the surface of cells)&#xD;
      than normal breast cells. Approximately 30% of patients with breast cancer have HER2 positive&#xD;
      breast cancer. Before HER2 targeted therapies (i.e. treatments that directly block the&#xD;
      receptor HER2) were developed, patients with HER2 positive breast cancer had a very&#xD;
      aggressive form of disease. With the use of trastuzumab, an anticancer drug that directly&#xD;
      targets the receptor HER2, and more recently, pertuzumab and ado-trastuzumab emtansine,&#xD;
      patients are able to live longer and have better control of their cancer.&#xD;
&#xD;
      Unfortunately the use of HER2 targeted therapies can increase the risk of heart problems and&#xD;
      for this reason these treatments were only studied and approved for patients with normal&#xD;
      heart function.&#xD;
&#xD;
      In this study we plan to give HER2 targeted therapies to patients with HER2 positive breast&#xD;
      cancer and mildly decreased heart function along with concomitant evaluation by a heart&#xD;
      doctor (called cardiologist) and appropriate medications to strengthen the heart. We will do&#xD;
      frequent monitoring of the heart function with a test called echocardiogram that will give us&#xD;
      a detailed &quot;picture&quot; of the heart. We will also draw blood along with routine blood tests to&#xD;
      try to understand why some patients develop heart problems and others do not. The study will&#xD;
      take a maximum of 12 months and patients will be monitored for 6 additional months.&#xD;
&#xD;
      We hypothesize that it is safe to administer HER2 targeted therapies to patients with breast&#xD;
      cancer and mildly decreased heart function, i.e. LVEF between 40 and 50%, while on&#xD;
      appropriate heart medications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title: A pilot study evaluating the cardiac safety of HER2 targeted therapy (non-lapatinib)&#xD;
      in patients with HER2 positive breast cancer and reduced left ventricular function Phase:&#xD;
      Pilot study Study Duration: 4 years with up to 5 additional years of follow up Study&#xD;
      Center(s): 3 centers will be participating: MedStar Washington Hospital Center (MWHC),&#xD;
      MedStar Georgetown University Hospital (MGUH) and Memorial Sloan Kettering Cancer Center&#xD;
      (MSKCC) Primary Objective: To evaluate the cardiac safety of HER2 targeted therapy&#xD;
      (non-lapatinib) in patients with HER2 positive breast cancer and reduced left ventricular&#xD;
      ejection fraction (LVEF) when given concomitantly with cardiac treatment.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To evaluate time to development of cardiac event or asymptomatic worsening of cardiac&#xD;
           function&#xD;
&#xD;
        -  Absolute changes in LVEF&#xD;
&#xD;
        -  Delays in HER2 therapy attributed to cardiac causes&#xD;
&#xD;
        -  Correlations between echocardiographic myocardial strain&#xD;
&#xD;
        -  cTnI and hs-cTnT at baseline and over time with cardiac events and asymptomatic&#xD;
           worsening of cardiac function Sample size: 30 patients&#xD;
&#xD;
      Diagnosis and Main Inclusion Criteria:&#xD;
&#xD;
        -  HER2 positive breast cancer, stage I-IV.&#xD;
&#xD;
        -  Mildly decreased cardiac function (LVEF between 40 and 49%) prior to or while receiving&#xD;
           non-lapatinib HER2 targeted therapy&#xD;
&#xD;
      Cardiac Intervention:&#xD;
&#xD;
      - Beta-blockers and ACE-inhibitors titrated to the maximum tolerated doses&#xD;
&#xD;
      Oncology study Products, Doses, Routes, Regimens:&#xD;
&#xD;
        -  Trastuzumab: loading dose of 8 mg/kg IV, followed by a maintenance dose of 6 mg/kg every&#xD;
           3 weeks, or a loading dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg every&#xD;
           week.&#xD;
&#xD;
        -  Pertuzumab: loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks, administered&#xD;
           concomitantly with trastuzumab.&#xD;
&#xD;
        -  Ado-trastuzumab emtansine: 3.6mg/kg IV every three weeks. Note: both trastuzumab and&#xD;
           pertuzumab may be administered alone or in combination with other systemic or radiation&#xD;
           therapy.&#xD;
&#xD;
      Duration of drug administration: Maximum of 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Actual">June 2020</completion_date>
  <primary_completion_date type="Actual">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Who Complete Planned Oncologic Therapy Without the Development of a Cardiac Event or Asymptomatic Worsening of Cardiac Function.</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>Cardiac events are defined as any of the following:&#xD;
Presence of symptoms attributable to heart failure as confirmed by a cardiologist&#xD;
Cardiac arrhythmia requiring pharmacological or electrical treatment&#xD;
Myocardial infarction&#xD;
Sudden cardiac death or death due to myocardial infarct, arrhythmia or heart failure&#xD;
Asymptomatic worsening of cardiac function defined as:&#xD;
- Asymptomatic decline in LVEF &gt; 10% points from baseline and/or EF &lt; 35% corroborated by a confirmatory echocardiogram in 2-4 weeks&#xD;
Planned oncologic therapy is defined as:&#xD;
In the adjuvant setting: completion of 1 year total of HER2 targeted therapy. If a patient already received part of the planned HER2 targeted therapy prior to enrollment in this trial, planned oncologic therapy will be achieved when a total of 1 year is completed.&#xD;
In the metastatic setting: cessation of treating regimen due to progressive disease or non-cardiac toxicity or non-cardiac death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Time to Development of an Event Defined as Cardiac Event or Asymptomatic Worsening of Left Ventricular Dysfunction, Among Patients Who Developed One Event.</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>Descriptive exploratory analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Changes in LVEF During HER2 Targeted Therapy</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>Descriptive exploratory analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HER2 Therapy Holds Attributed to Proportion of Patients With Symptomatic or Asymptomatic Cardiotoxicity.</measure>
    <time_frame>Up to 12 months.</time_frame>
    <description>Hold is defined as any delay or discontinuation of HER2 targeted therapy due to cardiac toxicity. One cycle of HER2 targeted therapy will be considered 3 weeks. One therapy hold will be defined as any 3-week HER2 targeted therapy missed dose or 1/3 if one weekly trastuzumab dose. For patients who had a hold and resumed HER2 targeted therapy, duration of treatment hold will be described.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Global Longitudinal Myocardial Strain With Cardiac Events and Asymptomatic Worsening of Cardiac Function</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>Descriptive exploratory analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Standard Cardiac Troponin I and Highly Sensitive Cardiac Troponin T With Cardiac Events and Asymptomatic Worsening of Cardiac Function</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>Descriptive exploratory analysis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>HER2 Positive Breast Cancer</condition>
  <condition>Left Ventricular Function Systolic Dysfunction</condition>
  <arm_group>
    <arm_group_label>HER2 therapies, cardiac medications</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cardiac intervention - beta-blockers and ACE-inhibitors titrated to the maximum tolerated doses&#xD;
Oncology intervention - patients will receive one of the three following HER2 targeted therapies at the discretion of the treating oncologist:&#xD;
Trastuzumab: loading dose of 8 mg/kg IV, followed by a maintenance dose of 6 mg/kg every 3 weeks, or a loading dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg every week.&#xD;
Pertuzumab: loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks, administered concomitantly with trastuzumab.&#xD;
Ado trastuzumab emtansine (TDM1): 3.6mg/kg IV every three weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>HER2 therapy</description>
    <arm_group_label>HER2 therapies, cardiac medications</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>HER2 therapy</description>
    <arm_group_label>HER2 therapies, cardiac medications</arm_group_label>
    <other_name>Perjeta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ado Trastuzumab Emtansine</intervention_name>
    <description>HER2 therapy</description>
    <arm_group_label>HER2 therapies, cardiac medications</arm_group_label>
    <other_name>Kadcyla</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female or male patient diagnosed with stage I-IV breast cancer&#xD;
&#xD;
          -  HER2 positive breast cancer, defined by immunohistochemical staining for HER2 protein&#xD;
             of 3+ intensity and/or amplification of the HER2 gene on fluorescence in situ&#xD;
             hybridization (FISH) ≥ 2.0 on breast specimen or biopsy of a metastatic site&#xD;
&#xD;
          -  LVEF &lt; 50% and ≥ 40% documented in echocardiogram done within the last 30 days&#xD;
&#xD;
          -  HER2 therapy naïve or currently receiving non-lapatinib HER2 targeted therapy&#xD;
&#xD;
          -  Patient receiving or planning to receive trastuzumab, trastuzumab with pertuzumab or&#xD;
             ado-trastuzumab emtansine, for at least 3 months, alone or in combination with other&#xD;
             systemic treatment or radiation&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Patient is willing and able to comply with protocol required assessments and&#xD;
             procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous hospitalization due to documented heart failure in the last 12 months&#xD;
&#xD;
          -  Current signs or symptoms of heart failure or ischemia&#xD;
&#xD;
          -  History of arrhythmia requiring pharmacological or electrical treatment&#xD;
&#xD;
          -  Concomitant use of anthracyclines or use of anthracyclines in the last 50 days&#xD;
&#xD;
          -  Pregnant or lactating patients. Patients of childbearing potential must implement&#xD;
             contraceptive measures during study treatment and for 7 months after last dose of&#xD;
             treatment drug and must have negative urine or serum pregnancy test within 7 days&#xD;
             prior to registration.&#xD;
&#xD;
          -  History of significant neurologic or psychiatric disorders including psychotic&#xD;
             disorders or dementia that would prohibit the understanding and giving of informed&#xD;
             consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra M Swain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington Cancer Institute at MedStar Washington Hospital Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington Cancer Institute at MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, Gallagher C, Pohlmann PR, Nunes R, Herbolsheimer P, Warren R, Srichai MB, Hofmeyer M, Cunningham A, Timothee P, Asch FM, Shajahan-Haq A, Tan MT, Isaacs C, Swain SM. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat. 2019 Jun;175(3):595-603. doi: 10.1007/s10549-019-05191-2. Epub 2019 Mar 9.</citation>
    <PMID>30852761</PMID>
  </results_reference>
  <results_reference>
    <citation>Lynce F, Barac A, Tan MT, Asch FM, Smith KL, Dang C, Isaacs C, Swain SM. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. Oncologist. 2017 May;22(5):518-525. doi: 10.1634/theoncologist.2016-0412. Epub 2017 Mar 17.</citation>
    <PMID>28314836</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 17, 2013</study_first_submitted>
  <study_first_submitted_qc>July 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2013</study_first_posted>
  <results_first_submitted>September 11, 2020</results_first_submitted>
  <results_first_submitted_qc>January 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 2, 2021</results_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer HER2 Positive</keyword>
  <keyword>Cardiac Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Ado-Trastuzumab Emtansine</mesh_term>
    <mesh_term>Maytansine</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>Journal Publicatopm</doc_type>
      <doc_url>https://theoncologist.onlinelibrary.wiley.com/doi/10.1634/theoncologist.2016-0412</doc_url>
    </study_doc>
  </study_docs>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT01904903/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HER2 Therapies, Cardiac Medications</title>
          <description>Cardiac intervention - beta-blockers and ACE-inhibitors titrated to the maximum tolerated doses&#xD;
Oncology intervention - patients will receive one of the three following HER2 targeted therapies at the discretion of the treating oncologist:&#xD;
Trastuzumab: loading dose of 8 mg/kg IV, followed by a maintenance dose of 6 mg/kg every 3 weeks, or a loading dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg every week.&#xD;
Pertuzumab: loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks, administered concomitantly with trastuzumab.&#xD;
Ado trastuzumab emtansine (TDM1): 3.6mg/kg IV every three weeks.&#xD;
Trastuzumab: HER2 therapy&#xD;
Pertuzumab: HER2 therapy&#xD;
Ado Trastuzumab Emtansine: HER2 therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HER2 Therapies, Cardiac Medications</title>
          <description>Cardiac intervention - beta-blockers and ACE-inhibitors titrated to the maximum tolerated doses&#xD;
Oncology intervention - patients will receive one of the three following HER2 targeted therapies at the discretion of the treating oncologist:&#xD;
Trastuzumab: loading dose of 8 mg/kg IV, followed by a maintenance dose of 6 mg/kg every 3 weeks, or a loading dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg every week.&#xD;
Pertuzumab: loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks, administered concomitantly with trastuzumab.&#xD;
Ado trastuzumab emtansine (TDM1): 3.6mg/kg IV every three weeks.&#xD;
Trastuzumab: HER2 therapy&#xD;
Pertuzumab: HER2 therapy&#xD;
Ado Trastuzumab Emtansine: HER2 therapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.6" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Non-Latino Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Latino White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Who Complete Planned Oncologic Therapy Without the Development of a Cardiac Event or Asymptomatic Worsening of Cardiac Function.</title>
        <description>Cardiac events are defined as any of the following:&#xD;
Presence of symptoms attributable to heart failure as confirmed by a cardiologist&#xD;
Cardiac arrhythmia requiring pharmacological or electrical treatment&#xD;
Myocardial infarction&#xD;
Sudden cardiac death or death due to myocardial infarct, arrhythmia or heart failure&#xD;
Asymptomatic worsening of cardiac function defined as:&#xD;
- Asymptomatic decline in LVEF &gt; 10% points from baseline and/or EF &lt; 35% corroborated by a confirmatory echocardiogram in 2-4 weeks&#xD;
Planned oncologic therapy is defined as:&#xD;
In the adjuvant setting: completion of 1 year total of HER2 targeted therapy. If a patient already received part of the planned HER2 targeted therapy prior to enrollment in this trial, planned oncologic therapy will be achieved when a total of 1 year is completed.&#xD;
In the metastatic setting: cessation of treating regimen due to progressive disease or non-cardiac toxicity or non-cardiac death.</description>
        <time_frame>Up to 18 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HER2 Therapies, Cardiac Medications</title>
            <description>Cardiac intervention - beta-blockers and ACE-inhibitors titrated to the maximum tolerated doses&#xD;
Oncology intervention - patients will receive one of the three following HER2 targeted therapies at the discretion of the treating oncologist:&#xD;
Trastuzumab: loading dose of 8 mg/kg IV, followed by a maintenance dose of 6 mg/kg every 3 weeks, or a loading dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg every week.&#xD;
Pertuzumab: loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks, administered concomitantly with trastuzumab.&#xD;
Ado trastuzumab emtansine (TDM1): 3.6mg/kg IV every three weeks.&#xD;
Trastuzumab: HER2 therapy&#xD;
Pertuzumab: HER2 therapy&#xD;
Ado Trastuzumab Emtansine: HER2 therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who Complete Planned Oncologic Therapy Without the Development of a Cardiac Event or Asymptomatic Worsening of Cardiac Function.</title>
          <description>Cardiac events are defined as any of the following:&#xD;
Presence of symptoms attributable to heart failure as confirmed by a cardiologist&#xD;
Cardiac arrhythmia requiring pharmacological or electrical treatment&#xD;
Myocardial infarction&#xD;
Sudden cardiac death or death due to myocardial infarct, arrhythmia or heart failure&#xD;
Asymptomatic worsening of cardiac function defined as:&#xD;
- Asymptomatic decline in LVEF &gt; 10% points from baseline and/or EF &lt; 35% corroborated by a confirmatory echocardiogram in 2-4 weeks&#xD;
Planned oncologic therapy is defined as:&#xD;
In the adjuvant setting: completion of 1 year total of HER2 targeted therapy. If a patient already received part of the planned HER2 targeted therapy prior to enrollment in this trial, planned oncologic therapy will be achieved when a total of 1 year is completed.&#xD;
In the metastatic setting: cessation of treating regimen due to progressive disease or non-cardiac toxicity or non-cardiac death.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Development of an Event Defined as Cardiac Event or Asymptomatic Worsening of Left Ventricular Dysfunction, Among Patients Who Developed One Event.</title>
        <description>Descriptive exploratory analysis</description>
        <time_frame>Up to 18 months.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Changes in LVEF During HER2 Targeted Therapy</title>
        <description>Descriptive exploratory analysis</description>
        <time_frame>Up to 18 months.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HER2 Therapy Holds Attributed to Proportion of Patients With Symptomatic or Asymptomatic Cardiotoxicity.</title>
        <description>Hold is defined as any delay or discontinuation of HER2 targeted therapy due to cardiac toxicity. One cycle of HER2 targeted therapy will be considered 3 weeks. One therapy hold will be defined as any 3-week HER2 targeted therapy missed dose or 1/3 if one weekly trastuzumab dose. For patients who had a hold and resumed HER2 targeted therapy, duration of treatment hold will be described.</description>
        <time_frame>Up to 12 months.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Global Longitudinal Myocardial Strain With Cardiac Events and Asymptomatic Worsening of Cardiac Function</title>
        <description>Descriptive exploratory analysis</description>
        <time_frame>Up to 18 months.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Standard Cardiac Troponin I and Highly Sensitive Cardiac Troponin T With Cardiac Events and Asymptomatic Worsening of Cardiac Function</title>
        <description>Descriptive exploratory analysis</description>
        <time_frame>Up to 18 months.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HER2 Therapies, Cardiac Medications</title>
          <description>Cardiac intervention - beta-blockers and ACE-inhibitors titrated to the maximum tolerated doses&#xD;
Oncology intervention - patients will receive one of the three following HER2 targeted therapies at the discretion of the treating oncologist:&#xD;
Trastuzumab: loading dose of 8 mg/kg IV, followed by a maintenance dose of 6 mg/kg every 3 weeks, or a loading dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg every week.&#xD;
Pertuzumab: loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks, administered concomitantly with trastuzumab.&#xD;
Ado trastuzumab emtansine (TDM1): 3.6mg/kg IV every three weeks.&#xD;
Trastuzumab: HER2 therapy&#xD;
Pertuzumab: HER2 therapy&#xD;
Ado Trastuzumab Emtansine: HER2 therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac event</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Allison Moses</name_or_title>
      <organization>MedStar</organization>
      <phone>301-256-2728</phone>
      <email>Allison.E.Moses@medstar.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

